The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults.
Data on the long-term safety of atovaquone/proguanil in nonimmune travelers are limited. An open-label study, involving 300 Danish soldiers stationed in Eritrea for 6 months was initiated. The subjects self-reported their symptoms on a post-travel questionnaire. The study compared the symptoms of compliers and noncompliers. No serious adverse events occurred. Diarrhea, stomach pain, headache, cough, and loss of appetite were the most common symptoms reported. No case of Plasmodium falciparum malaria occurred. Atovaquone/proguanil was safe and well tolerated in this group of long-term nonimmune travelers.